Diagonal Bio granted patent in Japan

Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) announces that the Japanese Patent Office has confirmed the grant of a patent (application number: EP3987059B1) to Diagonal Bio for the Company’s key technology (‘A DNA/RNA detection platform’).

At this stage, this patent protection has been extended to Europe, Hong Kong, Israel, Canada, Mexico, South Africa, the UK and Japan. The application is in process in additional countries such as the US, China and Australia.

“The granted patent in Japan further strengthens our position and protection. We are continuously working to protect our platform and inventions from different angles.” – Karin Wehlin, CEO of Diagonal Bio AB (publ)

For additional information about Diagonal Bio, please contact:
Karin Wehlin, CEO

Phone: +46 70 305 24 88

E-mail: kw@diagonalbio.com

About Diagonal Bio

Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio’s patented technology can also be used for the less regulated market segments via LAMPlify®.

Patent i Japan_250321